|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3738394041424344454647...6768» |
- bortezomib / Generic mfg.
Trial termination: Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients (clinicaltrials.gov) - Mar 17, 2014
P2/3, N=23, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Terminated; Very slow recruitment
- bortezomib / Generic mfg.
Enrollment change: Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients (clinicaltrials.gov) - Mar 17, 2014
P2/3, N=23, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Terminated; Very slow recruitment N=100 --> 23
- busulfan / Generic mfg.
Enrollment open: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 17, 2014
P0, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
N=100 --> 23 Not yet recruiting --> Recruiting
- ||| cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
Combination therapy: Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (clinicaltrials.gov) - Mar 13, 2014
P1/2, N=82, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Jakafi (ruxolitinib) / Novartis, Incyte
New P3 trial: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis (clinicaltrials.gov) - Mar 12, 2014
P3, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Enrollment open: A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=1800, Recruiting, Sponsor: Swedish Orphan Biovitrum
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Mar 12, 2014
P2, N=43, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Clinical: Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=40, Not yet recruiting, Sponsor: Amgen
- doxycycline / Generic mfg.
New P2 trial: A Phase II Study of Doxycycline in Relapsed NHL (clinicaltrials.gov) - Mar 11, 2014
P2, N=20, Not yet recruiting, Sponsor: University of Rochester
- Clinical data, Enrollment change: ETPOS: European Transfusion Practice and Outcome Study (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=6066, Completed, Sponsor: European Society of Anaesthesiology
Active, not recruiting --> Completed N=10000 --> 6066
- Clinical data, Trial completion: ETPOS: European Transfusion Practice and Outcome Study (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=6066, Completed, Sponsor: European Society of Anaesthesiology
N=10000 --> 6066 Recruiting --> Completed
- NovoSeven (eptacog alfa) / Novo Nordisk
New P1 trial: Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven (clinicaltrials.gov) - Mar 10, 2014
P1, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
P1 data: CHAMPION 2: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (clinicaltrials.gov) - Mar 9, 2014
P1, N=27, Recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Completed N=200 --> 27
- bortezomib / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial: Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma (clinicaltrials.gov) - Mar 6, 2014
P2, N=43, Not yet recruiting, Sponsor: Case Comprehensive Cancer Center
- lenalidomide / Generic mfg.
Trial termination: Lenalidomide After Allo Transplant (clinicaltrials.gov) - Mar 6, 2014
P1, N=1, Terminated, Sponsor: Beth Israel Deaconess Medical Center
N=200 --> 27 Recruiting --> Terminated
- lenalidomide / Generic mfg.
Enrollment change: Lenalidomide After Allo Transplant (clinicaltrials.gov) - Mar 6, 2014
P1, N=1, Terminated, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Terminated N=20 --> 1
- Enrollment open: Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. (clinicaltrials.gov) - Mar 6, 2014
P=N/A, N=40, Recruiting, Sponsor: Beth Israel Medical Center
N=20 --> 1 Not yet recruiting --> Recruiting
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change: Safety Study of AMG 531 in Japanese Subjects With ITP (clinicaltrials.gov) - Mar 4, 2014
P2, N=12, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting N=16 --> 12
- | carfilzomib / Generic mfg.
Clinical: CARAMEL 2: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (clinicaltrials.gov) - Mar 4, 2014
P2, N=43, Recruiting, Sponsor: Mayo Clinic
N=16 --> 12 Not yet recruiting --> Recruiting
- Trial withdrawal: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Withdrawn N=15 --> 0
- | Enrollment change: Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy (clinicaltrials.gov) - Mar 3, 2014
P2, N=18, Active, not recruiting, Sponsor: Cristina Gasparetto
N=15 --> 0 N=35 --> 18
- Avastin (bevacizumab) / Roche
New P2 trial: A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma (clinicaltrials.gov) - Mar 3, 2014
P2, N=10, Terminated, Sponsor: Hoffmann-La Roche
- |||||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
New P3 trial: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Mar 2, 2014
P3, N=100, Recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
- ||| Enrollment change: A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure (clinicaltrials.gov) - Feb 27, 2014
P4, N=2283, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
N=35 --> 18 N=3000 --> 2283
- ||| Enrollment closed: A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure (clinicaltrials.gov) - Feb 27, 2014
P4, N=2283, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
N=3000 --> 2283 Recruiting --> Active, not recruiting
- |||||||||| Tavalisse (fostamatinib) / Rigel
New P3 trial: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
- |||||||||| Tavalisse (fostamatinib) / Rigel
New P3 trial: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
- | lenalidomide / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P1/2 trial: Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 27, 2014
P1/2, N=45, Recruiting, Sponsor: New York University School of Medicine
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2014
P=N/A, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting N=13 --> 7
- IPH 2101 / Novo Nordisk, Innate
Enrollment change: KIRIMID: Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (clinicaltrials.gov) - Feb 26, 2014
P1, N=15, Completed, Sponsor: Innate Pharma
N=13 --> 7 N=30 --> 15
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 26, 2014
P=N/A, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
N=30 --> 15 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Enrollment closed: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Feb 26, 2014
P2, N=48, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | IPH 2101 / Novo Nordisk, Innate
Trial completion: KIRIMID: Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (clinicaltrials.gov) - Feb 26, 2014
P1, N=15, Completed, Sponsor: Innate Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, IO biomarker: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (clinicaltrials.gov) - Feb 26, 2014
P2, N=53, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial initiation date: Clinical Study of Lyophilized Plasma in Patients With Liver Disease (clinicaltrials.gov) - Feb 25, 2014
P2, N=100, Not yet recruiting, Sponsor: HemCon Medical Technologies, Inc
Active, not recruiting --> Completed Initiation date: Sep 2013 --> Jan 2015
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Feb 25, 2014
P2, N=12, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Initiation date: Sep 2013 --> Jan 2015 N=10 --> 12
- ||||| oprozomib (ONX 0912) / Amgen
New P1/2 trial: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 25, 2014
P1/2, N=74, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Feb 25, 2014
P2, N=12, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=10 --> 12 Active, not recruiting --> Completed
- ||| telaglenastat (CB-839) / Calithera
Metastases: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors (clinicaltrials.gov) - Feb 24, 2014
P1, N=65, Recruiting, Sponsor: Calithera Biosciences, Inc
- | Empliciti (elotuzumab) / AbbVie, BMS
Enrollment closed, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 23, 2014
P2, N=40, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- plerixafor / Generic mfg.
Trial completion: PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma (clinicaltrials.gov) - Feb 23, 2014
P2, N=44, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial completion: Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D (clinicaltrials.gov) - Feb 22, 2014
P2, N=45, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Active, not recruiting --> Completed
- | melphalan / Generic mfg.
Trial completion: Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=41, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | bortezomib / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Combination therapy: Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (clinicaltrials.gov) - Feb 22, 2014
P3, N=315, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed No longer recruiting --> Completed
- | sirolimus / Generic mfg.
Trial completion: Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg.
Trial completion, Metastases: An Open Protocol for the Compassionate Use of Thalidomide (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=250, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis (clinicaltrials.gov) - Feb 22, 2014
P2, N=47, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | arsenic trioxide / Generic mfg., pamidronate disodium / Generic mfg.
Trial completion, Combination therapy, Metastases: Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function (clinicaltrials.gov) - Feb 22, 2014
P1, N=150, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed